Methods of regulating disorders and diseases by inhibiting glycolysis within cells, including cancer cells, include administration of a compound that is one or more of: an antagonist of GPR55, an agonist of β2-adrenergic receptor (AR), or a compound that decreases expression and activity of EGFR, thereby reducing glycolysis in cancer cells. In embodiments, the compound is a fenoterol analogue, such as for example, MNF.
